Governance of preventive health intervention and on time verification of its efficiency: The GIOVE Study

BMJ Open

Volumn 2, Issue 2, 2012, Pages

  Mennini, Francesco Saverio ^a,b   Baio, Gianluca ^c,d   Montagano, Giuseppe ^e   Cauzillo, Gabriella ^e   Locuratolo, Francesco ^e   Becce, Gerardo ^e   Gitto, Lara ^a   Marcellusi, Andrea ^a   Zweifel, Peter ^f   Capone, Alessandro ^b   Favato, Giampiero ^b  

^a UNIVERSITY OF ROME TOR VERGATA   (Italy)

^b KINGSTON UNIVERSITY   (United Kingdom)

^c UNIVERSITY COLLEGE LONDON   (United Kingdom)

^d UNIVERSITY OF MILANO BICOCCA   (Italy)

^e Personal Services and the Community   (Italy)

^f UNIVERSITY OF ZURICH   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

WART VIRUS VACCINE;

ARTICLE; COHORT ANALYSIS; HEALTH CARE MANAGEMENT; HEALTH CARE QUALITY; HUMAN; IMMUNIZATION; ITALY; OBSERVATIONAL STUDY; ORGANIZATIONAL EFFICIENCY; PAPILLOMAVIRUS INFECTION; PATIENT COMPLIANCE; PREVENTIVE HEALTH SERVICE; RETROSPECTIVE STUDY; SCREENING TEST;

EID: 84860174907     PISSN: None     EISSN: 20446055     Source Type: Journal    
DOI: 10.1136/bmjopen-2011-000736     Document Type: Article

References (27)

1. Parkin DM, Bray F, Ferlay J, et al. Global cancer statistics, 2002. CA Cancer J Clin 2005;55:74-108. (Pubitemid 40372904)
2. Ferlay J, Bray F, Pisani P, et al. GLOBOCAN 2002: Cancer Incidence, Mortality and Prevalence Worldwide. IARC Cancer Base No. 5, Version 2.0. Lyon (France): IARC Press, 2004.
3. Ricciardi A, Largeron N, Giorgi Rossi P, et al. Incidence of invasive cervical cancer and direct costs associated with its management in Italy. Tumori 2009;95:146-52.
4. Costa S, Favato G. Evaluation of the Economic Impact Produced by the Prevention of Events Induced by the HPV 6-11Virus Types Contained in the Quadrivalent Vaccine. 2008. http://www.ssrn. com/abstract=1080113 (accessed 11 Apr. 2011).
5. Giorgi Rossi P, Ricciardi A, Choet C, et al. Epidemiology and costs of cervical cancer screening and cervical dysplasia in Italy. BMC Public Health 2009;9:71. http://www.biomedcentral.com/1471-2458/9/71 (accessed 11 Apr. 2011).
6. Coleman D, Day N, Douglas G, et al. European guidelines for quality assurance in cervical cancer screening. Eur J Cancer 1993;29A(Suppl 4):S1-38.
7. Kulasingam SL, Myers ER. Potential health and economic impact of adding a human papillomavirus vaccine to screening programs. JAMA 2003;290:781-9. (Pubitemid 37432955)
8. Taira AV, Neukermans CP, Sanders GD. Evaluating human papillomavirus vaccination programs. Emerg Infect Dis 2004;10:1915-23. (Pubitemid 39458555)
9. Goldie SJ, Kholi M, Grima D, et al. Projected clinical benefits and cost-effectiveness of a human papillomavirus 16/18 vaccine. J Natl Cancer Inst 2004;96:604-15. (Pubitemid 38584984)
10. Barnabas RV, Laukkanen P, Koskela P, et al. Epidemiology of HPV 16 and cervical cancer in Finland and the potential impact of vaccination: mathematical modelling analyses. PLoS Med 2006;3:624-32. (Pubitemid 43807031)
11. Elbasha EH, Dasbach EJ, Insinga RP. Model for assessing human papillomavirus vaccination strategy. Emerg Infect Dis 2007;13:28-41. (Pubitemid 46057835)
12. Dasbach E, Insinga R, Elbasha E. The epidemiological and economic impact of a quadrivalent human papillomavirus vaccine (6/11/16/18) in the UK. BJOG 2008. http://onlinelibrary.wiley.com/doi/10.1111/j.1471-0528.2008.01743.x/pdf (accessed 11 Apr. 2011).
13. Chesson HW, Ekwueme DU, Saraiya M, et al. Cost-effectiveness of human papillomavirus vaccination in the United States. Emerg Infect Dis 2008;14:244-51. (Pubitemid 351213674)
14. Mennini FS, Giorgi Rossi P, Palazzo F, et al. Health and economic impact associated with a quadrivalent HPV vaccine in Italy. Gynecol Oncol 2009;112:370-6.
15. Capri S, Bamfi F, Marocco A, et al. Impatto clinico ed economico della vaccinazione anti-HPV (clinical and economic impact of anti-HPV vaccination). Ital J Public Health 2007;4(2 Suppl 1):S36-54.
16. Rawlins MD, Culyer AJ. National Institute for Clinical Excellence and its value judgments. BMJ 2004;329:224-7. (Pubitemid 39013284)
17. Devlin N, Parkin D. Does NICE a cost-effectiveness threshold and what other factors influence its decisions? A binary choice analysis. Health Econ 2004;13:437-52. (Pubitemid 38660393)
18. Favato G, Pieri V, Mills R. Cost/Effective Analysis of Anti-HPV Vaccination Programme in Italy: A Multi-Cohort Markov Model. 2007. http://www.ssrn. com/abstract=961847 (accessed 11 Apr. 2011).
19. Cicchetti A, Ruggeri M, Mennini FS, et al. Analisi economica per l'estensione della vaccinazione contro l'influenza: risparmi sociali e analisi di Budget Impact. Pharmacoeconomics Italian Research Articles 2008;10:137-50. http://adisonline.com/pecitalian/Abstract/2008/10030/Analisi-economica-per-l- estensione-della.2.aspx (accessed 2 Mar. 2012).
20. Istituto nazionale di statistica (ISTAT). Popolazione Residente per età, sesso e stato civile al 1° gennaio 2006. http://demo.istat.it/ pop2006/index.html (accessed 11 Apr. 2011).
21. Mennini FS, Costa S, Favato G, et al. Anti-HPV vaccination: a review of recent economic data for Italy. Vaccine 2009;27:A54-61.
22. The Italian Ministry of Health. Principles and Objectives of the Ministry of health. http://www.ministerosalute.it/ministero/sezMinistero.jsp?label= principi (accessed 11 Apr. 2011).
23. Palmer S, Torgerson DJ. Definitions of efficiency. BMJ 1999;318:1136.
24. Weinstein M, Zeckhauser R. Critical ratios and efficient allocation. J Public Econ 1973;2:147-57.
25. Garber AM, Phelps CE. Economic foundations of cost-effectiveness analysis. J Health Econ 1997;16:1-31. (Pubitemid 27224092)
26. Cicchetti A, Ruggeri M, Gitto L, et al. Extending influenza vaccination to individuals aged 50-64: a budget impact analysis. Int J Technol Assess Health Care 2010;26:288-93.
27. Jit M, Chapman R, Hughes O, et al. Comparing bivalent and quadrivalent human papillomavirus vaccines: economic evaluation based on transmission model. BMJ 2011;343:5775.